This is the fifth installment in our 2026 Year in Preview series examining important trends in white collar law and ...

Westwood High School officials have released their first semester honor roll. ALL “As”: Mason Barbiere, *Elizabeth Bureau, ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's ...

Forbes contributors publish independent expert analyses and insights. Anisha Sircar is a journalist covering tech, finance and society. This voice experience is generated by AI. Learn more. This voice ...

In an interview with Bloomberg News, Eli Lilly Chief Financial Officer Lucas Montarce said that the Indiana-based pharma giant remains on track for a potential FDA approval of its obesity pill, ...

SAN FRANCISCO, Jan 12 (Reuters) - Nvidia (NVDA.O), opens new tab and U.S. pharma giant Eli Lilly (LLY.N), opens new tab will spend $1 billion building a new joint research lab in the San Francisco Bay ...

During the JPM Healthcare Conference, pharma giant Eli Lilly and Co. and NVIDIA announced a partnership to develop a San Francisco-based AI co-innovation lab, including an investment of up to $1 ...

In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...

Continental Strategy, the firm founded by former Donald Trump campaign adviser Carlos Trujillo, has been hired to represent the government of Kazakhstan.

Eli Lilly (LLY 1.51%) has behaved more like a tech stock in recent years than like a pharma stock. Tech players are known to soar in the double and triple digits when the environment and corporate ...

Eli Lilly (LLY) enters 2026 facing uncertainties in GLP-1 market pricing and competitive dynamics, prompting a HOLD/neutral rating. Lilly's international growth, especially for Monujaro, may slow as ...